1(3h)-isobenzofuranone
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2024 (NCT06488911)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- LeishmaniaINHIBITOR
Leishmania inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1(3h)-isobenzofuranone
- 1(3h)-isobenzofuranone, 7-hydroxy-6-methoxy-
- 7-hydroxy-6-methoxyphthalide
- ma-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06488911 | Phase 3 | Jul 1, 2024 | Intercept Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Intercept Pharmaceuticals | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1